IV / Subcut
    • Mechanism of Action
    • A fusion protein with the Fc fragment of human IgG1 linked to the extracellular domain of CTLA-4. Binds to CD80 / CD86 on antigen presenting cells and prevents binding by CD28 on T lymphocytes, resulting in lack of a costimulatory response and reduced T cell activation.

Clinical Use

    • Indications
    • Moderate to severe rheumatoid arthritis
    • Severe juvenile idiopathic arthritis
    • Psoriatic arthritis refractory to other DMARDs
    • Contraindications
    • Not to be used concurrently with other biologic DMARDs.
    • Adverse Effects
    • Injection site reactions
    • Infections (particuarly upper respiratory tract infection)
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Abdominal pain
    • Mouth ulcers
    • Hypertension
    • LFT derangement
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge